Last update Oct. 1, 2023
Alosetron is a 5-HT3 antagonist used for the treatment of irritable bowel syndrome (IBS) with predominantly severe diarrhea in women. Oral administration twice daily.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (very large volume of distribution and mode high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.
Its low oral bioavailability (even lower if taken with food) makes it difficult to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period where there may be greater intestinal permeability.
Possible exposure can be decreased by waiting 3 hours after taking the drug to resume breastfeeding.
We do not have alternatives for Alosetron Hydrochloride.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM